What are you actually choosing?
A useful comparison names the clinical decision, the access problem, and what would make the answer change.
Psychiatry comparisons
Side-by-side guides for the decisions people actually face: medication choices, treatment tradeoffs, coverage questions, and when two options aren't really equivalent.
The winner frame is usually weak
Side effects, cost, timing, diagnosis, history, and monitoring can make two reasonable options fit very different people.
Bring questions, not a verdict
The page should help a clinician reason with you, not replace the part where your actual history matters.
Low T vs. Depression: What You Actually Need to Know
Guys come in convinced they have low T when they're actually depressed, and other guys come in convinced they're depressed when their testosterone is in…
Jun 25, 2025
When to switch antidepressants, and when to stay
Half the antidepressant switches that happen shouldn't have happened, and the other half should have happened six months earlier.
Jan 27, 2025
Choosing between SSRIs, SNRIs, and what comes next
The decision tree for picking an antidepressant in 2026 isn't really a tree, it's more like a workflow, and the workflow is a lot simpler than the size of…
Jan 24, 2025
Adderall vs Vyvanse: side by side
Both are amphetamines, both work, the differences are real but not enormous, and the right answer for any given patient depends on factors that the rep…
Jan 22, 2025How to use these comparisons
A good comparison should make the tradeoff clearer, not flatten everything into a winner and a loser. Some choices are about side effects. Some are about cost, access, monitoring, or what has already failed. Some aren't medical choices at all, they're insurance or system choices that shape what care a person can actually get.
What the comparison is trying to answer
These articles focus on practical differences: what changes in day-to-day life, what a clinician is watching for, and what a patient should ask before switching, starting, stopping, or appealing a decision. The goal isn't to rank treatments like products. The goal is to name the real decision point.
Side effects are only one part of the trade
Side effects matter, but they aren't the whole decision. A medication that looks cleaner on paper may be harder to get, slower to work, more expensive, harder to stop, or less appropriate for a specific diagnosis. A treatment that sounds gentler may ask more of the patient every week. The comparison has to include the part that happens after the prescription or referral.
Cost and access count
Insurance rules, prior authorization, pharmacy stock, appointment availability, and out-of-pocket cost can turn a theoretically good option into a bad real-world plan. That doesn't make the cheaper or easier option automatically better. It means the access problem belongs in the decision instead of being treated like an afterthought.
Evidence isn't the same as fit
Strong evidence for a treatment means it works for a group of people under a defined set of conditions. It doesn't mean it's the right match for every person reading the page. Diagnosis, medical history, substance use, bipolar risk, trauma history, sleep, and the current medication list can all change the answer.
What belongs in this category
Medication comparisons belong here when the question is about choosing between options. Treatment comparisons belong here when the difference affects expectations, follow-up, or risk. Insurance and access comparisons belong here when the wrong path can waste weeks or months.
Switching is its own decision
A lot of comparison pages get used when someone is already on something and wondering whether to change. That's a different question than starting from zero. The current medication may be partially working, causing a tolerable side effect, preventing relapse, or masking a problem that will return when it's stopped. Switching deserves its own risk ledger.
The best answer may be sequencing
Sometimes the real choice isn't A versus B forever. It's what to try first, what to measure, how long to give it, and what comes next if the first step fails. A good comparison should make that sequence easier to see, especially when both options are reasonable but not equally urgent.
What not to take from a side-by-side article
A comparison can't tell you what's safe for your body, your history, or your medication list. It can help you walk into a visit with better questions. It can't replace the part where a prescriber looks at the whole picture.
How to bring it into a visit
Bring the comparison as a short list of questions, not as a verdict. Name the outcome you care about, the side effect you most want to avoid, the cost or access problem you're worried about, and what you've already tried. That gives the clinician something useful to work with instead of a generic request to be put on the one that sounded better online.
When two options aren't equivalent
Two choices can sit in the same conversation without doing the same job. One may treat acute symptoms while the other prevents relapse. One may be easier to start and harder to stop. One may be safer for one diagnosis and risky for another. Good comparison work keeps those differences visible, because a neat table can hide the part of the decision that actually matters.
What to write down before deciding
Before using any comparison, write down what you're trying to improve, what you can't tolerate, what you've already tried, what helped even a little, and what made things worse. That turns the article into a decision aid instead of a shopping list. It also makes the next visit more specific, which usually makes it more useful.
The middle option matters
Many decisions aren't simply continue or quit, this medication or that one, therapy or medication. The useful middle may be a dose change, a slower taper, a different formulation, a better sleep plan, a second diagnosis check, or a short period of measurement before a bigger change. Comparisons should leave room for that middle option because it's often where safer decisions happen.
Red flags in comparison advice
Be careful with any comparison that acts as if one option is always cleaner, newer, stronger, safer, or more natural. Those words can hide the actual trade. A page should tell you who the option may fit, who should be more cautious, what needs monitoring, and what kind of result would make the choice worth revisiting.
When to revisit a decision
A reasonable first choice can become the wrong choice when the situation changes. New side effects, pregnancy plans, substance use, a new diagnosis, unstable sleep, worsening anxiety, blood pressure changes, cost changes, or a pharmacy access problem can all shift the answer. The point of comparison isn't to make one final call forever. It's to make the next call with better information.
How the comparison pages should age
Some comparisons change as new evidence, labeling, coverage, supply, or clinical practice changes. When that happens, the page should get narrower or more current instead of pretending the old answer still covers the decision. If you notice a comparison that has aged badly, the editorial contact page is the right place to flag it.
When the cheaper option isn't simpler
Cost matters, but cheap doesn't always mean simple. A lower-cost medication may require more monitoring, more side effect management, or a slower titration. A cheaper care path may take longer to access or may not fit the actual diagnosis. Comparisons should name cost without letting cost pretend to be the whole clinical answer.
When the newer option isn't better
Newer options can be useful, especially when older choices failed or created intolerable side effects. But newer can also mean less familiarity, more insurance friction, less long-term experience, or a higher price for a modest benefit. A useful comparison should explain what's meaningfully different, not just what's newer.
What to compare after the first try
After the first try, the comparison changes. The next decision should use what actually happened: benefit, side effects, missed doses, cost, sleep, substance use, and whether the original target was measured. The best second choice isn't always the most popular alternative. It's the option that makes sense after the first real-world data point.